Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products - FDA Guidance Document

Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products - FDA Guidance Document | Global Key Solutions